Outcomes of second-line combination antiretroviral therapy for HIV-infected patients: a cohort study from Rio de Janeiro, Brazil

[1] Fox MP(2010)High rates of survival, immune reconstitution, and virologic suppression on second-line antiretroviral therapy in South Africa J Acquir Immune Defic Syndr 53 500-506

[2] Ive P(2011)Safety, Tolerability, and Efficacy of Second-Line Generic Protease Inhibitor Containing HAART after First-Line Failure among South Indian HIV-Infected Patients J Int Assoc Physicians AIDS Care (Chic) 10 71-75

[3] Long L(2010)Treatment failure and mortality factors in patients receiving second-line HIV therapy in resource-limited countries JAMA 304 303-312

[4] Maskew M(2010)Effectiveness of boosted protease inhibitor-based regimens in HIV type 1-infected patients who experienced virological failure with NNRTI-based antiretroviral therapy in a resource-limited setting AIDS Res Hum Retroviruses 26 139-148

[5] Sanne I(2011)Virologic and Immunologic Outcomes of the Second-Line Regimens of Antiretroviral Therapy Among HIV-Infected Patients in Thailand J Int Assoc Physicians AIDS Care (Chic) 10 57-63

[6] Kumarasamy N(2007)Drug resistance after failure of initial antiretroviral therapy in resource-limited countries Clin Infect Dis 44 453-455

[7] Venkatesh KK(2007)Options for a second-line antiretroviral regimen for HIV type 1-infected patients whose initial regimen of a fixed-dose combination of stavudine, lamivudine, and nevirapine fails Clin Infect Dis 44 447-452

[8] Devaleenal B(2007)Triple-class antiretroviral drug resistance: risk and predictors among HIV-1-infected patients AIDS 21 825-834

[9] Poongulali S(2009)The public health approach to identify antiretroviral therapy failure: high-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy AIDS 23 1127-1134

[10] Yepthomi T(2010)Varied patterns of HIV-1 drug resistance on failing first-line antiretroviral therapy in South Africa J Acquir Immune Defic Syndr 53 480-484

[1] Fox MP(2010)High rates of survival, immune reconstitution, and virologic suppression on second-line antiretroviral therapy in South Africa J Acquir Immune Defic Syndr 53 500-506

[2] Ive P(2011)Safety, Tolerability, and Efficacy of Second-Line Generic Protease Inhibitor Containing HAART after First-Line Failure among South Indian HIV-Infected Patients J Int Assoc Physicians AIDS Care (Chic) 10 71-75

[3] Long L(2010)Treatment failure and mortality factors in patients receiving second-line HIV therapy in resource-limited countries JAMA 304 303-312

[4] Maskew M(2010)Effectiveness of boosted protease inhibitor-based regimens in HIV type 1-infected patients who experienced virological failure with NNRTI-based antiretroviral therapy in a resource-limited setting AIDS Res Hum Retroviruses 26 139-148

[5] Sanne I(2011)Virologic and Immunologic Outcomes of the Second-Line Regimens of Antiretroviral Therapy Among HIV-Infected Patients in Thailand J Int Assoc Physicians AIDS Care (Chic) 10 57-63

[6] Kumarasamy N(2007)Drug resistance after failure of initial antiretroviral therapy in resource-limited countries Clin Infect Dis 44 453-455

[7] Venkatesh KK(2007)Options for a second-line antiretroviral regimen for HIV type 1-infected patients whose initial regimen of a fixed-dose combination of stavudine, lamivudine, and nevirapine fails Clin Infect Dis 44 447-452

[8] Devaleenal B(2007)Triple-class antiretroviral drug resistance: risk and predictors among HIV-1-infected patients AIDS 21 825-834

[9] Poongulali S(2009)The public health approach to identify antiretroviral therapy failure: high-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy AIDS 23 1127-1134

[10] Yepthomi T(2010)Varied patterns of HIV-1 drug resistance on failing first-line antiretroviral therapy in South Africa J Acquir Immune Defic Syndr 53 480-484